Protocol Details

Search for Novel Methods to Detect Acute Renal Failure

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	00-DK-0107
Sponsoring Institute	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 3 Max Age: N/A
Referral Letter Required	Yes
Population Exclusion(s)	None
Special Instructions	Currently Not Provided
Keywords	Acute Renal Failure; Biomarkers
Recruitment Keyword(s)	None
Condition(s)	Kidney Failure
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Institute of Diabetes and Digestive and Kidney Diseases

The purpose of this study is to find substances in the blood and urine that indicate that a person has kidney damage. It will identify proteins found only in patients with acute kidney failure but not in normal healthy people or in patients with volume depletion.

Adults and children who are at least 3 years old who fall into one of the following four categories may be eligible for this study:

1. Are healthy and have normal kidney function

2. Have volume depletion (this condition differs from acute kidney failure in that it is easily treated with fluids)

3. Are at high risk of kidney failure

4. Have acute kidney failure (kidney shutdown)

All study participants will have a history and physical examination. Up to four blood samples of 3 tablespoons each will be taken for laboratory analysis. Urine will be collected for analysis and to measure urine output. The participants' length of stay in the study varies. People with normal kidney function will be in the study for 1 day and patients with volume depletion will be studied 3 days. The length of hospitalization of patients at high risk of kidney failure or in acute kidney failure will depend on the patient's condition and medication requirements.

The results of this study may lead to the development of earlier and more accurate methods for diagnosing acute kidney failure. With earlier detection, treatment could be started earlier, possibly preventing further damage and helping recovery of injury that has already occurred.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Subjects greater than or equal to 3 years old. Both male and female subjects will be recruited without regard to race or ethnic origin.

Either:

Normal (creatinine level less than 1.3 mg/DL for adults; creatinine level less than standard nomogram for children); OR

Oliguria due to volume depletion (indicated by oliguria and Fractional Excretion of Sodium (FENa) of less than 1%); OR

High risk of ARF, including surgery, transplantation, nephrotoxic antibiotics, or bone marrow transplant; OR

Evidence of ARF as defined by an acute progressive rise in serum creatinine (at least 50% increase within 24 hours preceding enrollment) without stabilization or recovery, despite optimization of hemodynamic fluid status and correction of any known pharmacologic, pre-renal, or post-renal etiologic factors; OR

Urinary tract infection (to serve as control for ARF studies); OR

Established chronic kidney failure (to serve as control for ARF studies).

EXCLUSION CRITERIA:

Inability to give informed consent or cooperate with the study.

Existence of any other condition which would complicate the implementation or interpretation of the study.

--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
Robert A. Star, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health BG 2DEM RM 625 MSC 5458 6707 DEMOCRACY BLVD BETHESDA MD 20892-5458 (301) 496-6325 starr@mail.nih.gov	Peter S. Yuen, Ph.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health Building 10 Room 3N108 10 Center Drive Bethesda, Maryland 20892 (301) 402-6702 petery@mail.nih.gov	Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00026702

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

• Details on how to participate in a study
• Details on how to refer a patient to a study

NIH Clinical Studies Information Request

---

Contact the Office of Communications for:

• General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml

---

Contact the Department Clinical Research Informatics, (DCRI) for:

• Technical questions about Adobe Acrobat and the PDF format
• Technical questions about this web server

webmaster@cc.nih.gov